TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

NCT02641847 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

503

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer
Breast Cancer

Interventions

DRUG: docetaxel
DRUG: doxorubicin or epirubicin
DRUG: cyclophosphamide
DRUG: gemcitabine
DRUG: cisplatin

Sponsor

Fudan University